Entrar/Registro  
HOME SPANISH
 
Gaceta Médica de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Gaceta Médica de México >Year 2016, Issue 6


Palma-Ramos A, Castrillón-Rivera LE, Vega-Mémije ME, Arenas-Guzmán R, Rangel-Gamboa L
Presence of lactoferrin (LF) in lymphocutaneous sporotrichosis. Yeast-bound antimicrobial peptide
Gac Med Mex 2016; 152 (6)

Language: Español
References: 32
Page: 831-835
PDF: 550.23 Kb.


Full text




ABSTRACT

Sporotrichosis is a common subcutaneous mycosis in Latin America, produced by dimorphic fungi belong to Sporothrix schenckii complex of cryptic species. Infection is acquired by traumatic inoculation with contaminated organic material. Host immune response includes polymorphonuclear neutrophils chemotaxis and release of granular components. Lactoferrin is a protein member of the transferrin family of iron-binding proteins, present inside polymorphonuclear granular structure, and has been reported to affect growth and development of infectious agents, including fungal organisms. Nevertheless, lactoferrin expression in sporotrichosis infections has not been reported yet. Objective: To determine the expression of lactoferrin using immunohistochemical staining in sporotrichosis human infection. Material and methods: The dermatology department’s files during a period of five years were reviewed; cases with a diagnosis of sporotrichosis were selected and lactoferrin immunostaining was performed when enough biological material was available. Results: Three cases with a diagnosis of sporotrichosis and adequate biological material on paraffin block were identified. In all cases, lactoferrin immunostaining was positive around yeast cell.


Key words: Innate immunity, Lactoferrin, Sporothrix schenckii.


REFERENCIAS

  1. Campos P, Arenas R, Coronado H. Epidemic cutaneous sporotrichosis. Int J Dermatol. 1994;33(1):38-41.

  2. Coti IA. Epidemiology of sporotrichosis in Latin America. Mycopathologia. 1989;108(2):113-6.

  3. Bada-del-Moral M, Arenas R, Ruiz J. Esporotricosis en Veracruz. Estudio de cinco casos. Dermatol Rev Mex. 2007;51:9-13.

  4. Oliveira M, Almeida R, Muniz M, Gutierrez M, Zancope R. Phenotypic and Molecular Identification of Sporothrix isolates from an epidemic area of sporotrichosis in Brazil. Mycopathologia. 2011;172(4):257-67.

  5. Nicot J, Mariat F. [Morphological characteristics and systematic position of Sporothrix schenkii, the causative agent of human sporotrichosis]. Mycopathol Mycol Appl. 1973;49(1):53-65.

  6. Traynor TR, Huffnagle GB. Role of chemokines in fungal infections. Med Mycol. 2001;39(1):41-50.

  7. Loures FV, Pina A, Felonato M, Araújo EF, Leite KR, Calich VL. Toll-like receptor 4 signaling leads to severe fungal infection associated with enhanced proinflammatory immunity and ampaired expansion of regulatory T cells. Infect Immun. 2010;78(3):1078-88.

  8. Traynor TR, Huffnagle GB. Role of chemokines in fungal infections. Med Mycol. 2001;39(1):41-50.

  9. Blanco JL, Garcia ME. Immune response to fungal infections. Vet Immunol Immunopathol. 2008;125(1-2):47-70.

  10. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy ClinImmunol. 2008;122(2):261-6.

  11. Schaible UE, Collins HL, Priem F, Kaufmann SH. Correction of iron overload defect in β-2microglobulin knockout mice by lactoferrina abolishes their susceptibility to tuberculosis. J Exp Med. 2002;196(11): 1507-13.

  12. Rodriguez-Franco DA, Vazquez-Moreno L, Ramos-Clamont G. [Antimicrobial mechanisms and potential clinical application of lactoferrin]. Rev Latinoam Microbiol. 2005;47(3-4):102-11.

  13. Drago-Serrano M. Actividades antibacterianas de la lactoferrina. Enf Inf Microbiol. 2006;26:58-63.

  14. Gonzalez-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents. 2009;33(4):301.e1-8.

  15. Barhill R, Crowson N. Dermatopathology. 2.a ed. McGraw-Hill; 2004. p. 496.

  16. Lurie HI. Histopathology of sporotrichosis. Notes on the nature of the asteroid body. Arch Pathol. 1963;75:421-37.

  17. Parrow NL, Fleming RE, Minnick MF. Sequestration and Scavenging of Iron in Infection. Infect Immun. 2013;81(10):3503-14.

  18. Skaar EP. The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathogens. 2010;6(8):e1000949.

  19. Drago-Serrano ME, Garza-Amaya M, Serrano-Luna JS, Campos-Rodriguez R. Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. IntImmunopharmacol. 2012;12(1): 1-9.

  20. Kirkpatrick CH, Green I, Rich RR, Schade Al. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrina: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J Infect Dis. 1971;124(6):539-44.

  21. Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S, Tomita M. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrina. Med MicrobiolImmunol. 1993;182(2):97-105.

  22. Samaranayake YH, Samaranayake LP, Wu PC, So M. The antifungal effect of lactoferrina and lysozyme on Candida krusei and Candida albicans APMIS. 1997;105(11):875-83.

  23. Mishra B, Leishangthem GD, Gill K, et al. A novel antimicrobial peptide derived from modified N-terminal domain of bovine lactoferrina: Design, synthesis, activity against multidrug-resistant bacteria and Candida. Biochim Biophys Acta. 2013;1828(2):677-86.

  24. Van der Does AM, Bogaards SJ, Ravensbergen B, Beekhuizen H, van Dissel JT, Nibbering PH. Antimicrobial peptide hLF1-11 directs granulocyte- macrophage colony-stimulating factor- driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother. 2010;54(2):811-6.

  25. Spadaro M, Caorsi C, Ceruti P, et al. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J. 2008;22(8):2747-57.

  26. Tomita M, Wakabayashi H, Shin K, Yamauchi K, Yaeshima T, Iwatsuki K. Twenty-five years of research on bovine lactoferrin applications. Biochimie. 2009;91(1):52-7.

  27. Takakura N, Wakabayashi H, Ishibashi H, et al. Effect of orally administered bovine lactoferrina on the immune response in the oral candidiasis murine model. J Med Microbiol. 2004;53(Pt 6):495-500.

  28. Palma A, Castrillon L, Espinosa V, Becerril D, Padilla M, Arenas-Guzman R. Existencia de lactoferrina en granos de micetoma: estudio de ocho actinomicetomas humanos. Dermatol Rev Mex. 2014;58:142-9.

  29. Martinez-Álvarez JA, Pérez-García LA, Flores-Carreón A, Mora-Montes HM. The immune response against Candida spp. and Sporothrixschenckii. Rev Iberoam Micol. 2014;31(1):62-6.

  30. Bolscher J, Nazmi K, van Marle J, van’t Hof W, Veerman E. Chimerization of lactoferricin and lactoferrampin peptides strongly potentiates the killing activity against Candida albicans. Biochem Cell Biol. 2012;90(3):378-88.

  31. Silva T, Adão R, Nazmi K, et al. Structural diversity and mode of action on lipid membranes of three lactoferrincandidacidal peptides. Biochim Biophys Acta. 2013;1828(11):1329-39.

  32. Viejo-Diaz M, Andrés MT, Fierro JF. Different anti-Candida activities of two human Lactoferrin-derived peptides, Lfpep and kaliocin-1. Antimicrob Agents Chemother. 2005;49(7):2583-8.






>Journals >Gaceta Médica de México >Year 2016, Issue 6
 

· Journal Index 
· Links 






       
Copyright 2019